von Hippel-Lindau disease
Drug research and approvals for von Hippel-Lindau disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 17 studies of von Hippel-Lindau disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · Not applicable · Peking University First Hospital · starts Apr 27, 2026
- Belzutifan VHL RCC HK Prospective RegistryNCT07554508 · Not reported · Chinese University of Hong Kong · starts Dec 22, 2025
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)NCT07405164 · Phase 3 · Merck Sharp & Dohme LLC · starts Mar 23, 2026
- CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau DiseaseNCT07171905 · Phase 2 · IRCCS Ospedale San Raffaele · starts Feb 25, 2026
- Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialNCT07167329 · Phase 2 · José Claudio Casali da Rocha · starts Jan 1, 2024
- Institutional Registry of Rare DiseasesNCT06573723 · Not reported · Hospital Italiano de Buenos Aires · starts Jul 1, 2024
- A Study of HS-10516 in Patients With VHL Syndrome Associated TumorsNCT06553339 · Phase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · starts Jul 19, 2024
- Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsNCT06523582 · Not reported · Universidad Nacional Autonoma de Mexico · starts Aug 3, 2022
- Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule CellsNCT06194669 · Not reported · IRCCS San Raffaele · starts Jun 30, 2023
Approved 1
- BelzutifanEndothelial PAS domain-containing protein 1 inhibitor
Phase 2 6
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- VatalanibStem cell growth factor receptor inhibitor
- DovitinibFibroblast growth factor receptor 3 inhibitor
- FludeoxyglucoseDiagnostic agent
- Geldanamycin
Phase 1 or earlier 5
- RanibizumabVascular endothelial growth factor A inhibitor
- Pegaptanib sodiumVascular endothelial growth factor A antagonist
- DigoxinSodium/potassium-transporting ATPase inhibitor
- Pegpleranib sodiumPlatelet-derived growth factor subunit B inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
How its trials ended
49 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 10 whose ending is known, 20% met their primary endpoint, 10% missed it and 70% stopped early.
- Ongoing2347%
- Completed, result not reported1429%
- Stopped: enrollment or feasibility36%
- Stopped: other or unclear36%
- Met its primary endpoint24%
- Status unknown24%
- Missed its primary endpoint12%
- Stopped: safety12%
| Aug 13, 2021 | WeliregTreatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central… | Merck Sharp & Dohme, LLC | Approved |
| Mar 23, 2000 | 3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-oneTreatment of von Hippel-Lindau disease. | Sugen, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA